Prospective systematic classification of causes of death in the course of multiple myeloma - Summary - MDSpire

Prospective systematic classification of causes of death in the course of multiple myeloma

  • By

  • Jia xiang Jin

  • Britta Besemer

  • Büsranur Yilmaz

  • Mathias Hänel

  • Roland Fenk

  • Uta Bertsch

  • Kaarina-Jiayuan Gu

  • Christine Hanoun

  • Igor W. Blau

  • Christoph Mann

  • Christof Scheid

  • Roland Schroers

  • Ivana von Metzler

  • Manfred Hensel

  • Eva-Maria Klein

  • Martin Hoffmann

  • Christoph Lutz

  • Hendrik Riesenberg

  • Uwe M. Martens

  • Christian S. Michel

  • Christian Kunz

  • Evgenii Shumilov

  • Deniz Gezer

  • Tobias A. W. Holderried

  • Karolin Trautmann-Grill

  • Carsten Müller-Tidow

  • Katja C. Weisel

  • Marc S. Raab

  • Hans J. Salwender

  • Hartmut Goldschmidt

  • Elias K. Mai

  • October 20, 2025

  • 0 min

Share

Objective:

To elucidate causes of death (COD) trajectories, identify patterns of COD fluctuations, and reveal notable COD trends in multiple myeloma (MM) patients, emphasizing the importance of these insights for clinical decision-making.

Key Findings:
  • 83% of known COD were MM-dependent, primarily due to MM progression (50%) and therapy-related causes (19%), highlighting the need for targeted interventions.
  • A notable rise in therapy-associated COD was observed during the COVID-19 pandemic, particularly infections, indicating a shift in patient risk profiles.
  • Survival analysis indicated significant differences in survival rates based on COD categories, especially during the pandemic, suggesting the need for tailored patient management strategies.
Interpretation:

The study highlights the evolving landscape of causes of death in MM, particularly the impact of therapy and external factors like the COVID-19 pandemic on patient outcomes, which may inform future clinical practices.

Limitations:
  • 19% of cases had unknown COD, which were excluded from further analysis, potentially introducing bias.
  • The study is limited to data from specific clinical trials and a registry, which may not be generalizable to all MM patients.
Conclusion:

The findings underscore the need for ongoing monitoring of COD in MM patients to inform clinical decision-making and improve patient management.

Original Source(s)

Prospective systematic classification of causes of death in the course of multiple myeloma

  • by Jia xiang Jin, Britta Besemer, Büsranur Yilmaz, Mathias Hänel, Roland Fenk, Uta Bertsch, Kaarina-Jiayuan Gu, Christine Hanoun, Igor W. Blau, Christoph Mann, Christof Scheid, Roland Schroers, Ivana von Metzler, Manfred Hensel, Eva-Maria Klein, Martin Hoffmann, Christoph Lutz, Hendrik Riesenberg, Uwe M. Martens, Christian S. Michel, Christian Kunz, Evgenii Shumilov, Deniz Gezer, Tobias A. W. Holderried, Karolin Trautmann-Grill, Carsten Müller-Tidow, Katja C. Weisel, Marc S. Raab, Hans J. Salwender, Hartmut Goldschmidt, Elias K. Mai

  • October 20, 2025

Related Content

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Computed tomography-derived sarcopenia, enteral nutritional support, and febrile neutropenia burden in children with acute lymphoblastic leukemia: a retrospective cohort study